| 1+ ADL |  | Depression |  | Poor self-rated health |  | WHOQoL score |  |
---|---|---|---|---|---|---|---|---|
 | OR (95 % CI) | OR (95 % CI) | OR (95 % CI) | Beta coefficient (95 % CI) | ||||
 | Model 1 | Model 2 | Model 1 | Model 2 | Model 1 | Model 2 | Model 1 | Model 2 |
Main effects | Â | Â | Â | Â | Â | Â | Â | Â |
Angina | 2.15*** | 2.74*** | 1.98*** | 2.89*** | 2.15*** | 2.66*** | −3.49*** | −3.79*** |
(1.96–2.34) | (2.35–3.2) | (1.76–2.21) | (2.32–3.56) | (1.97–2.35) | (2.25–3.11) | (−3.87 to –3.09) | (−4.47 to –3.11) | |
Arthritis | 2.15*** | 2.75*** | 2.06*** | 2.54*** | 1.84*** | 2.28*** | −2.96*** | −3.69*** |
(1.99–2.32) | (2.43–3.12) | (1.85–2.28) | (2.13–3.03) | (1.7–1.99) | (1.98–2.61) | (−3.28 to –2.64) | (−4.24 to –3.13) | |
Asthma | 1.50*** | 1.84*** | 1.71*** | 2.24*** | 1.57*** | 1.72*** | −2.61*** | −3.18*** |
(1.31–1.72) | (1.4–2.39) | (1.45–2.00) | (1.58–3.07) | (1.35–1.79) | (1.25–2.29) | (−3.2 to –2.02) | (−4.35 to –1.99) | |
Chronic lung disease | 2.02*** | 2.48*** | 2.14*** | 2.28*** | 2.00*** | 2.8*** | −2.74*** | −3.36*** |
(1.8–2.25) | (2.03–3.04) | (1.86–2.44) | (1.73–2.98) | (1.79–2.22) | (2.23–3.42) | (−3.21 to –2.26) | (−4.35 to –1.99) | |
Diabetes | 1.31*** | 1.38** | 1.16** | 1.51** | 1.83*** | 2.29*** | −2.26*** | −3.4*** |
(1.16–1.47) | (1.07–1.76) | (0.97–1.35) | (1.08–2.06) | (1.61–2.07) | (1.79–2.88) | (−2.77 to –1.74) | (−4.35 to –1.99) | |
Hypertension | 1.04 | 1.05 | 0.98 | 1.09 | 1.05 | 1.02 | 0.01 | 0.02 |
(0.97–1.11) | (0.95–1.16) | (0.88–1.08) | (0.93–1.26) | (0.98–1.13) | (0.92–1.15) | (−0.25–0.26) | (−0.32–0.38) | |
Low vision | 1.28*** | 1.33*** | 1.23*** | 1.25** | 1.19*** | 1.26*** | −0.89*** | −0.94*** |
(1.19–1.36) | (1.19–1.47) | (1.11–1.35) | (1.07–1.45) | (1.11–1.28) | (1.11–1.43) | (−1.15 to –0.62) | (−1.15 to –0.62) | |
Stroke | 2.40*** | 2.36*** | 2.21*** | 2.17*** | 2.22*** | 2.18*** | −4.28*** | −4.25*** |
(1.99–2.86) | (1.97–2.81) | (1.75–2.73) | (1.73–2.7) | (1.86–2.62) | (1.83–2.57) | (−5.08 to –3.5) | (−5.04 to –3.47) | |
Two-way interactions | Â | Â | Â | Â | Â | Â | Â | Â |
Arthritis × Angina |  | 0.78*** |  | 0.64*** |  | 0.79** |  | 0.69** |
 | (0.65–0.92) |  | (0.51–0.81) |  | (0.67–0.93) |  | (−0.09–1.5) | |
Arthritis × Chronic lung disease |  | 0.73** |  | 0.84* |  | 0.82** |  | 1.17** |
 | (0.57–0.9) |  | (0.64–1.08) |  | (0.66–1.03) |  | (0.11–2.2) | |
Arthritis × Asthma |  | 0.8* |  | 0.83 |  | 0.73** |  | 1.34** |
 | (0.59–1.05) |  | (0.59–1.14) |  | (0.54–0.95) |  | (0.05–2.64) | |
Arthritis × Low vision |  | 0.82** |  | 0.99 |  | 0.95 |  | 0.14 |
 | (0.7–0.94) |  | (0.81–1.22) |  | (0.82–1.11) |  | (−0.5–0.78) | |
Arthritis × Diabetes |  | 0.95 |  | 0.88 |  | 0.87 |  | 1.56** |
 | (0.73–1.21) |  | (0.61–1.23) |  | (0.67–1.1) |  | (0.39–2.73) | |
Angina × Chronic lung disease |  | 0.86* |  | 1.17 |  | 0.78** |  | 0.72* |
 | (0.69–1.06) |  | (0.88–1.52) |  | (0.63–0.95) |  | (−0.32–1.75) | |
Angina × Asthma |  | 0.81* |  | 0.85 |  | 0.86 |  | 0.71 |
 | (0.6–1.06) |  | (0.61–1.13) |  | (0.65–1.1) |  | (−0.56–1.99) | |
Angina × Low vision |  | 0.99 |  | 1.05 |  | 0.90* |  | −0.43 |
 | (0.83–1.16) |  | (0.84–1.28) |  | (0.75–1.05) |  | (−1.19–0.33) | |
Angina × Diabetes |  | 0.92 |  | 0.79* |  | 0.96 |  | −0.03 |
 | (0.69–1.22) |  | (0.54–1.11) |  | (0.73–1.24) |  | (−1.3–1.23) | |
Asthma × Low vision |  | 1.04 |  | 1.06 |  | 1.00 |  | −0.08 |
 | (0.78–1.36) |  | (0.77–1.45) |  | (0.76–1.31) |  | (−1.25–1.15) | |
Asthma × Diabetes |  | 1.31 |  | 1.32 |  | 0.65** |  | 1.26 |
 | (0.81–2.02) |  | (0.77–2.07) |  | (0.41–0.99) |  | (−0.79–3.32) | |
Hypertension × Arthritis |  | 0.96 |  | 1.02 |  | 0.92 |  | 0.28 |
 | (0.83–1.11) |  | (0.83–1.23) |  | (0.79–1.06) |  | (−0.36–0.92) | |
Hypertension × Angina |  | 0.84** |  | 0.63*** |  | 1.03 |  | 0.04 |
 | (0.7–0.99) |  | (0.5–0.79) |  | (0.87–1.22) |  | (−0.71–0.78) | |
Hypertension × Lung disease |  | 0.93 |  | 1.05 |  | 0.93 |  | −0.10 |
 | (0.75–1.17) |  | (0.8–1.36) |  | (0.76–1.15) |  | (−1.05–0.84) | |
Hypertension × Asthma |  | 1.02 |  | 1.01 |  | 1.53*** |  | −1.07** |
 | (0.77–1.32) |  | (0.72–1.37) |  | (1.16–1.99) |  | (−2.28–0.16) | |
Hypertension × Low vision |  | 1.06 |  | 1.01 |  | 1.03 |  | 0.02 |
 | (0.93–1.21) |  | (0.84–1.22) |  | (0.89–1.19) |  | (−0.49–0.55) | |
Hypertension × Diabetes |  | 1.25** |  | 1.11 |  | 1.12 |  | −0.37 |
 | (0.98–1.57) |  | (0.79–1.53) |  | (0.87–1.41) |  | (−1.4–0.64) | |
Low vision × Diabetes |  | 0.74** |  | 0.7** |  | 0.85* |  | 1.73*** |
 | (0.57–0.92) |  | (0.5–0.95) |  | (0.66–1.06) |  | (0.71–2.73) | |
Chronic lung disease × Asthma |  | 0.86 |  | 0.76** |  | 0.90 |  | 0.54 |
 | (0.65–1.12) |  | (0.54–1.02) |  | (0.68–1.17) |  | (−0.69–1.77) | |
Chronic lung disease × Low vision |  | 1.10 |  | 0.99 |  | 0.92 |  | −0.30 |
 | (0.88–1.35) |  | (0.76–1.28) |  | (0.75–1.12) |  | (−1.26–0.64) | |
Chronic lung disease × Diabetes |  | 1.05 |  | 1.00 |  | 0.67** |  | 0.39 |
 | (0.74–1.48) |  | (0.66–1.45) |  | (0.47–0.91) |  | (−1.23–1.97) | |
Random part | Â | Â | Â | Â | Â | Â | Â | Â |
Country | 1.04 | 0.97 | 0.80 | 0.85 | 0.26 | 0.25 | 9.71 | 10.38 |
(0.24–3.56) | (0.21–3.31) | (0.17–2.89) | (0.18–3.02) | (0.05–0.91) | (0.05–0.84) | (2.18–34.24) | (2.35–35.84) | |
Province | 0.30 | 0.30 | 0.41 | 0.39 | 0.21 | 0.21 | 3.66 | 3.67 |
(0.2–0.43) | (0.2–0.43) | (0.25–0.63) | (0.24–0.62) | (0.14–0.31) | (0.14–0.31) | (2.5–5.3) | (2.49–5.34) | |
Individual | Na | na | na | na | na | na | 116.5 (114.7–118.4) | 116.4 (114.5–118.2) |